X

Trial Profile

Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in BCMA+ Refractory/Relapsed Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0120 (Primary)
Indications Multiple myeloma; Plasma cell leukaemia
Focus Adverse reactions; First in man

Most Recent Events

17 Jun 2022 Updated results assessing the safety and preliminary efficacy for FAST-CAR GC012F in RRMM patients from studies (NCT04236011; NCT04182581) presented at the 27th Congress of the European Haematology Association
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
26 May 2022 Results published in the Gracell Biotechnology Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com